S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
New Trump Bombshell (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
New Trump Bombshell (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
New Trump Bombshell (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
New Trump Bombshell (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
New Trump Bombshell (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
New Trump Bombshell (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
New Trump Bombshell (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
New Trump Bombshell (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
New Trump Bombshell (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
New Trump Bombshell (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
New Trump Bombshell (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
New Trump Bombshell (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage

Aptose Biosciences (APS) Competitors

C$2.44
+0.01 (+0.41%)
(As of 02/23/2024 08:54 PM ET)

APS vs. HBP, ATE, MBX, RVX, AEZS, MDNA, BCT, ONC, TH, and MDP

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Helix BioPharma (HBP), Antibe Therapeutics (ATE), Microbix Biosystems (MBX), Resverlogix (RVX), Aeterna Zentaris (AEZS), Medicenna Therapeutics (MDNA), BriaCell Therapeutics (BCT), Oncolytics Biotech (ONC), Theratechnologies (TH), and Medexus Pharmaceuticals (MDP). These companies are all part of the "medical" sector.

Aptose Biosciences vs.

Helix BioPharma (TSE:HBP) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Helix BioPharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Aptose Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Aptose Biosciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A N/A -111.88%
Aptose Biosciences N/A -180.44%-81.22%

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Helix BioPharma'saverage media sentiment score.

Company Overall Sentiment
Helix BioPharma Neutral
Aptose Biosciences Neutral

Helix BioPharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$5.94M-C$0.03-5.67
Aptose BiosciencesN/AN/A-C$49.25M-C$10.40-0.23

12.0% of Aptose Biosciences shares are held by institutional investors. 21.7% of Helix BioPharma shares are held by insiders. Comparatively, 24.7% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Helix BioPharma has a beta of -0.74, suggesting that its stock price is 174% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Aptose Biosciences received 146 more outperform votes than Helix BioPharma when rated by MarketBeat users. Likewise, 72.11% of users gave Aptose Biosciences an outperform vote while only 63.46% of users gave Helix BioPharma an outperform vote.

CompanyUnderperformOutperform
Helix BioPharmaOutperform Votes
66
63.46%
Underperform Votes
38
36.54%
Aptose BiosciencesOutperform Votes
212
72.11%
Underperform Votes
82
27.89%

Summary

Aptose Biosciences beats Helix BioPharma on 7 of the 10 factors compared between the two stocks.


Get Aptose Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APS vs. The Competition

MetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$38.33MC$595.11MC$4.82BC$3.80B
Dividend Yield0.39%3.47%5.40%7.15%
P/E Ratio-0.23234.08243.8528.01
Price / SalesN/A20,999.923,017.371,244.43
Price / Cash1.6013.0790.7172.85
Price / Book2.375.154.383.11
Net Income-C$49.25M-C$49.70MC$108.96MC$269.04M
7 Day Performance-6.87%10.05%112.79%0.49%
1 Month Performance-7.58%14.02%121.55%0.89%
1 Year Performance187.06%70.73%133.28%3.39%

Aptose Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
0 of 5 stars
C$0.18
+5.9%
N/A-15.0%C$39.00MN/A-6.009Gap Up
ATE
Antibe Therapeutics
0 of 5 stars
C$0.95
+2.2%
N/A+83.9%C$50.04MC$9.71M-2.7111Positive News
Gap Up
MBX
Microbix Biosystems
0 of 5 stars
C$0.41
flat
N/A+14.3%C$55.30MC$16.51M-19.50N/A
RVX
Resverlogix
0 of 5 stars
C$0.06
-14.3%
N/A-60.0%C$16.33MN/A-1.2019Gap Up
AEZS
Aeterna Zentaris
0 of 5 stars
C$2.42
+0.4%
N/A-42.9%C$11.76MC$6.86M-0.3711
MDNA
Medicenna Therapeutics
0 of 5 stars
C$1.02
+6.3%
N/A+55.6%C$71.03MN/A-6.0016News Coverage
Gap Up
BCT
BriaCell Therapeutics
0 of 5 stars
C$4.62
+7.2%
N/AN/AC$73.83MN/A-1.9816Gap Down
ONC
Oncolytics Biotech
0.553 of 5 stars
C$1.51
-3.2%
C$9.00
+496.0%
-37.2%C$110.83MN/A-2.9629Upcoming Earnings
TH
Theratechnologies
1.332 of 5 stars
C$2.27
+1.8%
C$5.50
+142.3%
+56.0%C$111.68MC$79.73M-1.36144Analyst Revision
Gap Up
MDP
Medexus Pharmaceuticals
0 of 5 stars
C$1.64
-6.3%
N/AN/AC$40.11MC$115.72M4.2198Positive News

Related Companies and Tools

This page (TSE:APS) was last updated on 2/26/2024 by MarketBeat.com Staff